The objectives were as follows: Firstly, to estimate the overall probability of event-free survival (EFS) and isolated CNS relapse in the studies for children with acute lymphoblastic leukemia ( 
Introduction
In the 1970s there was a breakthrough in the improvement of outcome for childhood acute lymphoblastic leukemia (ALL). The development of prophylactic cranial irradiation greatly contributed to the improvement of outcome of childhood ALL. 1, 2 Trials to reduce the utilization of cranial irradiation had already been initiated in the 1970s and the results were reported in 1980. 3, 4 From the 1980s to 1990s, fundamental prognostic factors such as age, leukocyte count, cell lineage and chromosomal abnormalities were elucidated and applied to the risk-adopted strategy. 5 The multi-agent intensive induction and intensification regimens were developed in this era. Varieties of randomized comparative studies were executed as large-scale studies. [6] [7] [8] The Tokyo Children's Cancer Study Group (TCCSG) started prophylactic cranial irradiation in the protocol of 1975. A randomized trial for ALL was opened in 1981 9 with the participation of 23 institutions. Currently, 42 major institutions (listed in the appendix) in the Tokyo metropolitan area and other districts are participating.
The first objective of this article is to estimate the overall probability of EFS and isolated CNS relapse in the studies between 1981 and 1995 in TCCSG. The second objective is to evaluate the EFS according to essential presenting features and lineage for each regimen, and the third is to evaluate the treatment results according to the risk groups of NCI criteria. This may provide insights that will lead to better treatment of children with ALL.
Materials and methods
From 1981 to 1995, 1450 previously untreated children aged 1 to 15 with acute lymphoblastic leukemia (ALL) were entered and 1438 were eligible for the four consecutive studies of Tokyo Children's Cancer Study Group (TCCSG): L81-10 (1981-1984 , 189 patients), (Table 1) , 9 L84-11 (1984) (1985) (1986) (1987) (1988) (1989) , 484 patients) ( Table 2) , [10] [11] [12] L89-12 (1989-1992, 418 patients) (Table 3) 13 -16 and L92-13 (1992-1995, 347 patients) EFS, event-free survival; s.e., standard error; CNS, central nervous system; NCI, National Cancer Institute criteria. Infants were treated differently and retrospectively analyzed in Table 5 .
Lineage, patients who were tested and positive for E-rosette or SmIg were excluded from this study. a Randomized control studies in SR arms (P = 0.1419, not significant) and b in HR arms (P = 0.6139, not significant) by logrank test.
( Table 4 ). The results have been published elsewhere. 17 All the patients with B-ALL were treated with the B lymphoma protocol of the TCCSG. T cell ALL was excluded from L81-10. Infants less than 12 months of age were treated individually. Sixty-two infants who were treated between 1977 and 1995 were retrospectively surveyed ( Table 5 ). The results have been published elsewhere. 18 The diagnosis of ALL was made according to the morphology of Giemsa staining and negative peroxidase reaction in L81-10. E-rosette positive T cell type and surface immunoglobulin positive B cell type were excluded. In L84-11, monoclonal antibodies were utilized as markers of the lineage determination. Cerebrospinal fluid infiltration of leukemic cells was called positive if more than 5/l mononuclear cells were counted and positive for lymphoblasts by cytology. The success rate of obtaining analyzable karyotypes of leukemic cells has been low, ranging from 20 to 30% in these studies, particularly when specimens were mailed to the laboratory. DNA index measured by flow cytometry was evaluated only for a proportion of the patients on L92-13. The proposed protocols were accepted with the decision of each department, and have been performed after obtaining informed consent from the patients.
Treatment
An abbreviated summary of regimens in each protocol is presented in Table 6 . In the L81-10 study, 9 195 patients were enrolled and 189 patients were eligible. Six patients were not eligible because of the lack of essential information for the diagnosis or for risk classification. A randomized comparison was performed in the standard risk (SR) group between 18 and 24 Gy prophylactic cranial irradiation. In the high risk group, intensifications every 12 weeks were randomized between doxorubicin and cyclophosphamide (arm HRCY+) and no cyclophosphamide (arm HRCY−). All patients were treated for 5 years. Standard risk was defined as a presenting leukocyte count less than 20 × 10 9 /l and 1 to 6 years of age (Table 6 ). All the others were treated with the high risk regimen (HR).
In the L84-11 study, 490 patients were enrolled and 484 patients were eligible for analysis. Six patients were registered with no telephone in advance for randomization and were ineligible. An extremely high risk (HEX) group was separated from HR if the leukocyte count was 100 × 10 9 /l or more, or if the patients had T-ALL or a mediastinal mass. Both SR and HR groups were randomized at early intensification to receive (S2, H2) or not receive (S1, H1) three courses of intermediatedose methotrexate (ID-MTX 500 mg/m 2 ). The details of the L84-11 protocol were given in earlier publications. [10] [11] [12] In the L89-12 protocol, [13] [14] [15] [16] which enrolled 418 eligible patients, a main objective was to determine whether or not cranial irradiation was essential for standard risk patients. The SR group was randomized into two arms at CNS directed therapy (Table 6 ). SR0 signifies an arm in which patients were given three courses of high-dose methotrexate (HD-MTX 3 g/m 2 ) with six ITs (three double ITs and three triple ITs, EFS, event-free survival; s.e., standard error; CNS, central nervous system; NCI, National Cancer Institute criteria. Infants were treated differently and retrospectively analyzed in Table 5 . a,b Randomized control studies in SR ( a P = 0.0552) and HR ( b P = 0.2661).
c See text about the definition of arms. d Lineage information was not available in the rest of the patients. Table 6 ) as CNS-directed therapy. In the SR18 arm, the patients received 18 Gy of prophylactic cranial irradiation with the same ITs. Randomization ratio between the arms was changed from 1:1 to 2:1 in the middle of the study in order to reduce the number of irradiated children. Patients were assigned to the HEX risk if they were older than 10 years, 7 to 9 years with leukocytes count Ͼ20 × 10 9 /l, were Ph chromosome positive or if they had 11q23 abnormality. Response to a 1 week prednisolone prophase 16 (previously reported by the BFM group 19 ) with no intrathecal methotrexate was also studied for its prognostic value.
In L92-13, which enrolled 347 patients, a major objective was to access the abbreviated 6 months maintenance therapy in all three risk groups. The second objective was to clarify the efficacy of early intensification with high-dose cytosine arabinoside and mitoxantrone. The third objective was a randomized study of the omission of cranial irradiation in HR risk patients with a leukocyte count less than 50 × 10 9 /l. The full report of this study was recently published. 17 
Leukemia
Infants younger than 12 months of age were ineligible for protocols in this paper. Therefore, treatment of infants was variable. Since 1995, infants with ALL have been enrolled on the Japanese Infant Leukemia Study Group.
Statistical analysis
The duration of event-free survival (EFS) was defined as the time from the initiation of therapy to the date of failure (any relapse, death or diagnosis of secondary cancer) or to the last day when the patient was confirmed to be well. Patients who did not achieve complete remission after the first induction phase or who died before the confirmation of remission, were considered to have failed at day 0. Probability of EFS was estimated by the Kaplan-Meier method and was tested for significant differences using the logrank test. Patients who were inadvertently or intentionally treated in the different regimens were analyzed according to their randomized treatment. Probability rate of cumulative isolated CNS relapse, and any CNS relapse was estimated by the inverse Kaplan-Meier method (to subtract the calculated products from 1.0). The patients who relapsed in other sites or died in remission were all censored.
Results

Long-term follow-up
The follow-up results are summarized in Table 7 . All the patients have been followed up once a year except for those in the L81-10 who were followed-up once every 2 to 3 years. Patients who received modified treatment were censored on the spot. When drug dosage was reduced or completely omitted because of complications the patients were analyzed without being censored. 91.7% of event-free patients in the L81-10 protocol were seen between 1996 and 1998. 98.0% of event-free patients in L84-11, 98.0% in L89-12, and 98.4% in L92-13 were seen within the last 2 years.
Protocol-specific treatment outcome
L81-10 ( Figure 1 , Table 1 ) 9 
:
Of the 189 patients, 183 (96.8%) achieved complete remission. The overall event-free survival (±1 s.e.) at 5 years was 56.5 ± 3.8%. The median (minimum-maximum) follow-up duration for patients who were free of failure was 15.3 (8.9-17.7) years. The cumulative risk of isolated CNS relapse at 5 years was 8.1 ± 2.3% and that of CNS relapse with or without any other site was 10.9 ± 2.6%. There was a superior event-free survival in the arm with the 18 Gy cranial irradiation (SR18, 81.7 ± 58% at 5 years) than the 24 Gy arm (SR24, 62.3 ± 8.0% at 5 years) of SR, although it was not statistically significant (P = 0.1419). EFS, event-free survival; s.e., standard error; CNS, central nervous system; NCI, National Cancer Institute criteria. Infants were treated differently and retrospectively analyzed in Table 5 . There were three CNS relapses in each arm. No significant difference in EFS was observed between the two HR arms (38.6 ± 7.3%, 45.8 ± 7.3% at 5 years). Table 2 ) [10] [11] [12] : Remission induction was successful in 472 (97.5%) of 484 patients. The overall event-free survival at 5 years was 71.0 ± 2.1%. The median (minimum-maximum) follow-up duration for the patients who were free of failure was 13.2 (9.1-15.9) years. The 5 year cumulative risk of isolated CNS relapse was 3.5 ± 0.9% and that of any CNS relapse namely with or without any other site Leukemia was 5.2 ± 1.1%. The CNS prophylaxis in this protocol consisted of five triple ITs in conjunction with 18 Gy (SR) or 24 Gy (HR) cranial irradiation during 2 to 3 weeks. There were 22 cases of myelopathy and leukoencephalopathy of various severities distributed in all five treatment arms. Numbers of patients with CNS complication at CR (death in CR) in each arm were: 4 (2) in S1, 4 (0) in S2, 3 (1) in H1 (2), 6 (2) in H2 and 5 (0) in HEX, respectively.
L84-11 (Figures 2 and 3,
The patients on the S2 arm, which was intensified with three courses of ID-MTX at early post-remission phase, showed superior event-free survival to those on S1 arm, which included no ID-MTX (Figure 3) . The P value (estimated by log- rank test) was of borderline significance (0.0552). There was a tendency that the H1 arm was superior in EFS to the H2 arm but the difference was not statistically significant (Table 2, Figure 3 ). In addition, there were 10 boys with testicular relapse with or without any other sites in the S1 arm, whereas there were only two in the S2 arm. This difference most probably derived from the effect of early ID-MTX in S2. Figure 4, Table 3 ) [13] [14] [15] [16] :
L89-12 (
The remission induction rate in L89-12 was 92.6% (387/418). This was lower than any other protocol because of 12 deaths during remission induction due to the profound bone marrow suppression resulting in pulmonary fungal infections. The dose of THP-adriamycin was reduced from 30 to 20 mg/m 2 after the interim analysis. The risk of early death was avoided thereafter.
The overall 5 year EFS was 67.8 ± 2.3%. The median (minimum-maximum) follow-up period of the patients who were free of failure was 9.2 (6.9-10.7) years. The 5 year cumulative risk of isolated CNS relapse was 3.6 ± 1.0% and CNS relapse with or without any other site was 5.1 ± 1.1%. There was no significant difference in event-free survival or CNS relapse between the two SR regimens (logrank test P = 0.3144).
The initial response to the steroid correlated well with prognosis. 16, 19 The poor prednisolone responders (PPR) who retained absolute lymphoblast counts over 1000/l in the peripheral blood at day 8 tended to fail early and had signifiLeukemia cantly lower EFS (39.6 ± 6.3% at 5 years) than the good presnisolone responders (GPR) (EFS 73.4 ± 2.4% at 5 years, P Ͻ 0001). Figure 5 depicts the results of combined analysis for NCI risk and initial steroid response, showing remarkable significance as a predicting factor of early failure in PPR at either risk. Figure 6 , Table 4 ) 18 
L92-13 (
:
Three hundred and thirtythree out of 347 patients (96.0%) entered complete remission treated with L92-13 protocol. The overall event-free survival at 5 years was 63.4 ± 2.7%. The median (minimummaximum) follow-up period for the patients who remained in remission was 6.3 (4.5-7.5) years. The 5 year cumulative risk of isolated CNS relapse was 1.0 ± 0.6% and that of CNS relapse with or without any other site was 2.6 ± 1.0%. The short maintenance therapy most adversely affected the eventfree survival of SR (65.9 ± 4.3% at 5 years), resulting in almost the same level of EFS as that of HR and HEX. The EFS of the HEX group was 60.4 ± 5.4%, which was as high as the previous protocols. There was no significant difference between the HR arms with cranial irradiation vs the other arm with high-dose methotrexate, either in the EFSs or in the cumulative rate of CNS relapse.
Infant ALL (Table 5):
Sixty-two infants younger than 12 months who were not enrolled in the studies were retrospectively analyzed. 18 The overall 5 year EFS was 13.1 ± 4.8%.
Figure 1
Probability of event-free survival in L81-10 protocol (n = 189) and cumulative rate of central nervous system relapse. Event-free survival was estimated by Kaplan-Meier (K-M) method. The cumulative rate of CNS relapse was estimated by subtracting the relapse-free rate (K-M product) from 1.0 (same in Figures 2, 3, 4, 6 ).
There were 17 CNS relapses (44.7% of all the relapses). Infants who were CD10 negative, 11q23 positive, or who had a leukocyte count more than 50 × 10 9 /l had a worse prognosis, as has been previously reported. 20 
Secondary malignancies:
Secondary malignancy, whether therapy related or not, was considered as a failure. There were four secondary AML and four MDS after treatment on the last three protocols; 21 four on L84-11, three on L89-12, and one on L92-13. Topoisomerase II inhibitors (etoposide, doxorubicin, THP-adriamycin) had been used in seven of these eight patients. The interval from the diagnosis of ALL to the secondary leukemia ranged from 25 to 58 months in patients treated with topoisomerase inhibitors and 79 months in the other patient. We experienced a high incidence of secondary AML from the T lymphoma protocol. 21, 22 However, none of the eight patients with ALL was T-ALL. This is contrary to reports from other centers. 22, 23 Seven cases developed in first remission. Two patients showed t(9;11) associated with 11q23 break points. All but one expired. Three brain tumors were reported among the patients, two in the L84-11 and one in the L89-12. 24 The pathological diagnoses were gliomas in the two cases that developed at 75 and 96 months from the diagnosis of ALL. The third patient
Figure 2
Probability rate of event-free survival in L84-11 protocol (n = 484) and cumulative rate of central nervous system relapse.
Figure 3
Probability rate of event-free survivals in five arms of L84-11 protocol (n = 484).
seemed not to be a secondary malignancy because it occurred at 40 weeks of chemotherapy of ALL, and 5 months after cranial irradiation. No pathological diagnosis was obtained from the last patient. The overall incidence of brain tumors among our patients has been low so far, but they are still at risk since they may occur for up to 15 years. 25 An olfactory neuroblastoma developed at 10 years after chemotherapy of L84-11 and autologous bone marrow transplantation.
Figure 4
Probability rate of event-free survival in L89-12 protocol (n = 418) and cumulative rate of central nervous system relapse.
Figure 5
Probability rate of event-free survival in L89-12 protocol, classified by NCI/Rome risk criteria and prednisolone response. Good prednisolone responder means a patient who retained peripheral blood blasts count less than 1 × 10 9 /l at day 8 after treatment of prednisolone only. Poor prednisolone responder means a patient who retained those over 1 × 10 9 /l.
Treatment results according to presenting features in each era (Tables 1-4)
There was a tendency that girls did better than boys in all the four protocols. P value, however, was 0.0965 (not significant)
Leukemia
Figure 6
Probability rate of event-free survival in L92-13 protocol (n = 374) and cumulative rate of central nervous system relapse.
by logrank test in L81-10. It was significant at P = 0.00577 in L84-11, 0.01175 in L89-12, and 0.0299 in L92-13 protocol. When testicular relapse was censored, the significance disappeared although females still did better than males. 13 The sex difference is pronounced in the SR groups and not obvious in the higher risk groups. 13 According to the NCI/Rome risk criteria, 26 'SR' was defined as a presenting leukocyte count less than 50 × 10 9 /l and 1 to 9 years of age. The percentages of SR in B-precursor ALL patients enrolled in each protocol were 73.5% (66.8% when adjusted for the omission of T-ALL), 62.0%, 57.7% and 55.6%, respectively. The NCI risk was an excellent criterion in all the protocols among patients with B-precursors.
T-ALL usually comprises 10 to 15% of childhood ALL under the age of 16. 27 In L84-11, only 6.6% of patients were T cell ALL, while they comprised 10.3% of L89-12. EFS of the T-ALL was remarkably stable through all three protocols even though overall EFS decreased in L92-13. The EFSs of T-ALL were 59.4 ± 8.7% in L84-11, 57.1 ± 7.7% in L89-12 and 59.3 ± 8.6% in L92-13. SR T-ALL patients by NCI criteria did better than B-precursors in protocols L89-12 (EFS, 72.7 ± 13.4%) and L92-13 (EFS, 77.1 ± 14%), but did not in L84-11 (55.6 ± 16.6%).
Cumulative incidence of isolated CNS relapse reached 10.6 ± 2.8, 4.1 ± 1.0%, 3.6 ± 1.0% and 1.0 ± 0.65 in the four studies. This reflects the combined effects of the repeated intrathecal injections and ID-MTX in L84-11, HD-MTX and intensified systemic therapy in L89-12.
Overall survival had been steadily improving during this period (Tables 1-4) , despite the stable EFS in L89-12 and worse EFS in L92-13. They were 60.9 ± 3.6% in L81-10, 76.7 ± 1.9% in L84-11 and 74.6 ± 2.1 in L89-12 at 8 years, and 78.6 ± 2.3% in L92-13 at 7.5 years.
Discussion
In the TCCSG studies, there was a remarkable improvement of the long-term outcome in L84-11 when compared to the previous L81-10 protocol. In L84-11 the CNS-directed therapy was significantly intensified. The CNS prophylaxis in this protocol consisted of five triple ITs along with 18 Gy (SR) or 24 Gy (HR) cranial irradiation for 2 to 3 weeks and early intensification with ID-MTX in S2 and H2 regimens. As a result, the isolated CNS relapses in L84-11 significantly decreased from 10.4% in L81-10 to 4.1%. There were, however, 22 cases of myelopathy and/or leukoencephalopathy of various severities in all five treatment; five of them died in remission. There was no other probable cause for the unexpected CNS toxicities than the five triple ITs lasting for the 2 to 3 weeks along with cranial irradiation. Those CNS complications occurred in both randomized arms of SR and HR almost equally, irrespective of the preceding ID-MTX to the delayed cranial irradiation.
The lowest incidence of CNS relapse was obtained in the L92-13 study. However, caution should be used in the interpretation of the lower CNS relapse rate on protocol L92-13 since a higher rate of bone marrow failure might mask patients who would have had a later CNS relapse. Another possibility is that high-dose cytosine arabinoside might be useful in preventing CNS relapse.
In L89-12, the proportion of patients at various risks was comparable to the international standard. The duration of therapy was 2 years in all risks. The EFS levels were reasonable except for the 12 early deaths during induction. The evaluation of the initial prednisolone response demonstrated strong correlation with early failure in both SR and HR groups ( Figure 6 ). In our current protocol, L99-15, early response to steroid is used as one of the risk factors for stratification.
Testicular relapse has been a major problem, and was an important cause for the inferior EFS in males to females in TCCSG protocols. 13 The 10-17% cumulative isolated testicular relapse in our first two studies decreased to 1.0-3.9% in the more recent protocols. As the comparative study in SR of the L84-11 had shown, early intensification with ID-MTX may well be the solution for this problem, at least in SR.
Results of the L92-13 study emphasized the importance of more prolonged standard maintenance therapy, particularly for SR patients. At the same time, it is likely that a substantial fraction of patients could be cured by only 1 year of therapy. Biological tests to detect patients who will do well with shorter treatment are needed. Perhaps measurement of minimal residual disease at the end of induction will fulfill this role. Many late relapsers on the L92-13 protocol were rescued by stem cell transplantation or intensive chemotherapy. The overall survival rate at 7.5 years for the study is higher than those in the previous studies.
The NCI criteria 26 worked very well even among the patients who were treated with different therapy intensity. This means that the biology of the disease relates strongly to age and leukocyte counts at diagnosis and is not easily affected even by intensive chemotherapy.
The percentage of patients in each NCI risk group and the percentage in each lineage category should be constant, if accrual is complete. There might have been accrual bias in our studies since these proportions varied. Alternatively, some of these differences might reflect differences in the monoclonal antibodies used or in local expertise in using these antibodies. Registration of consecutive patients from all participating centers is essential to avoid selection bias.
